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Summary 
Degradation of structural elements and excessive consumption of humoral factors, especially of 
plasma proteinase inhibitors, by proteolysis and/or oxidation is a major cause of multiple organ 
failure in sepsis or septic shock. Such pathobiochemical reactions seem to be induced primarily by 
extracellularly liberated lysosomal proteins from PMN granulocytes (e.g. elastase, cathepsin G, 
myeloperoxidase, lactoferrin) as well as oxygen radicals produced during extensive phagocytosis. 
In clinical studies on septicemia and septic shock the consumption of plasma proteins including 
proteinase inhibitors was inversely correlated to the liberation of lysosomal factors, especially the 
granulocytic elastase. Administration of relatively specific elastase-cathepsin G-inhibitors (Bow-
man-Birk inhibitor, eglin) in experimental septicemia proved to be a promising therapeutic ap-
proach to reduce consumption of plasma proteinase inhibitors and development of interstitial lung 
edema in severe inflammation. 
Zusammenfassung 
Die Zerstörung von Gewebesubstanzen und der übermäßige Verbrauch humoraler Faktoren, 
insbesondere von Plasma-Proteinaseinhibitoren durch Proteolyse und/oder Oxidation wird als 
eine wichtige Ursache für das multiple Organversagen in der Sepsis bzw. dem septischen Schock 
angesehen. Derartige path obio chemische Prozesse dürften vorwiegend durch extrazellulär frei-
gesetzte lysosomale Proteine (z. B. Elastase, Cathepsin G, Myeloperoxidase, Laktoferrin etc.) und 
oxidierende Produkte hervorgerufen werden, die während einer verstärkten Phagozytosetätig-
keit gebildet werden. In klinischen Studien zur Septikämie bzw. zum septischen Schock war der 
Verbrauch von Plasmaproteinen einschließlich der Proteinaseinhibitoren invers korreliert zur 
Freisetzung lysosomaler Faktoren, insbesondere der PMN Elastase. Die Anwendung relativ spe-
zifischer Elastase/Cathepsin G-Inhibitoren (Bowman-Birk-Inhibitor, Eglin) in experimentellen 
Sepsisstudien erwies sich als vielversprechender therapeutischer Ansatz, dem übermäßigen Ver-
brauch von Proteinaseinhibitoren und der Ausbildung eines interstitiellen Lungenödems bei 
schweren entzündlichen Erkrankungen entgegen zu wirken. 
Key Words: Antithrombin I I I , Bowman-Birk inhibitor, cathepsin G, eglin, elastase, factor 
X I I I , inhibitor imbalance, inhibitor therapy, inflammation, lactoferrin, lyso-
somal factors, a'2-macroglobulin, myeloperoxidase, a rproteinase inhibitor, 
P M N granulocytes, septicemia, septic shock, unspecific proteolysis. 
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Introduction 
Despite of numerous studies concerned with 
sepsis or septic shock, the pathogenesis of this 
disease is still discussed controversially. How-
ever, evidence accumulates that leukocytes, 
particularly the polymorphonuclear (PMN) 
granulocytes, may play a central role in the de-
velopment of multiple organ failure in severe 
septicemia. Invasion of P M N granulocytes 
into the inflamed area is triggered by produc-
tion of chemoattractants such as leuko-
trienes, fibrin/ogen degradation products, 
complement-derived anaphylatoxins (C5a, 
C3a) etc. as well as by increased vascular per-
meability due to e.g. liberation of kinins from 
kininogens. During the attachment to and en-
gulfment of invasive organisms and cell debris 
in the infectious focus, the granulocytes re-
lease various aggressive substances extracellu-
larly (e.g. oxygen radicals, hydrolytic and 
proteolytic enzymes) which in turn may im-
pair structural elements (basal membranes, 
elastin, collagen, fibronectin, proteolycans 
etc.) as well as humoral factors (especially pro-
teins of the "blood systems": clotting, fib-
rinolysis, complement, and kallikrein-kinin 
system) [for review of literature, see1]. 
Application of up-to-date biochemical 
techniques in clinical research revealed very 
recently that extracellular release of 
granulocytic products is substantially corre-
lated with the outcome of patients suffering 
from sepsis or septic shock2. Hence, elucida-
tion of the underlying pathomechanisms may 
provide more successful tools for prophylaxis 
and therapy. 
This report mainly deals with two topics: (i) 
the considerable consumption of plasma pro-
teinase inhibitors due to augmented liberation 
of lysosomal proteins and/or enhanced activa-
tion of blood system proteinases, (ii) a 
therapeutic approach to overcome the often 
lethal consequences of the proteinase inhibitor 
deficit in the organism. 
Lysosomal Factors of PMN Granulocytes 
Lysosomal factors are liberated from various 
body cells under pathological conditions. In 
this respect P M N granulocytes, which are at-
tracted during severe inflammatory processes 
in high amounts in the primary shock organs 
(lungs, liver and kidneys), are of special in-
terest. These cells are equipped with a power-
ful proteolytic, hydrolytic and oxidizing po-
tential in their lysosomes, enabling physiolog-
ically the intracellular protein catabolism as 
well as degradation of phagocytized extracel-
lular material in the phagolysosomes3. 
Of the lysosomal proteinases known so far, 
elastase and cathepsin G, the neutral pro-
teinases from the azurophilic granules of 
P M N granulocytes are most interesting be-
cause of their occurrence in high quantities 
within the granules and their very low 
substrate specificity 4 , 5. When liberated ex-
tracellularly, these proteinases degrade and in-
activate various plasma proteins as, for exam-
ple, the proteinase inhibitors antithrombin 
I I I , a2-plasmin inhibitor and Cl-inac-
tivator 6 , 7 , before the enzymes are inhibited by 
their major antagonists, (X\-proteinase in-
hibitor, a'j-antichymotrypsin and a^-macro-
globulin. Moreover, an amplification of the 
elastolytic activity due to the combined action 
of both elastase and cathepsin G has been re-
ported recently8. 
Myeloperoxidase - also localized in the 
azurophilic granules - catalyzes the reaction 
of hydrogen peroxide ( H 2 O 2 ) with chloride 
ions (CI") in the phagolysosomes, thus form-
ing various oxidants which are strongly bac-
tericidal 9. 
The antibacterial effect of lactoferrin, which is 
primarily produced in the specific granules of 
granulocytes (but also in body cells such as 
glandular epithelial cells), is well established. 
Patients with recurrent infections as a con-
sequence of lack of specific granules and lac-
toferrin as well have been described only re-
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cently. Moreover, several promoting and in-
hibiting effects of lactoferrin have been pro-
posed. However, most of the studies could 
not be confirmed by others and even con-
tradictory results were reported. Hence, at 
present the functional role of lactoferrin in in-
flammation is still an open question 1 0. 
Activation and Consumption of Blood Pro-
teins 
If the forementioned proteins - especially the 
proteinases - are released extracellularly, the 
inflammatory response may be enhanced via 
two major routes1: 
Selective or limited proteolysis leads to proen-
zyme and/or cofactor activation of the blood 
systems (clotting, fibrinolysis, complement, 
kallikrein-kinin system) and to the formation 
of biologically highly potent peptides such as 
kinins, anaphylatoxins and fibrin/ogen degra-
dation products. Unspecific proteolysis espe-
cially due to the action of elastase and cathep-
sin G destroys not only blood system factors, 
immunoglobulins and many other proteins 
but also proteinase inhibitors simply by pro-
teolytic digestion. 
Normally, selective activation of blood sys-
tems and unspecific proteolysis are kept under 
a well-balanced control by potent and specific 
plasma proteinase inhibitors 1 1 : 
Antithrombin III (AT III) regulates clotting, 
a2-plasmin inhibitor (oc2PI) fibrinolysis, and 
Cl-inactivator (CI-INA) both, the classical 
complement pathway and the intrinsic coagu-
lation cascade. The latter is achieved by inhib-
ition of plasma kallikrein and Hageman factor 
respectively its low molecular weight frag-
ment. 
The occurrence of complexes between oc2-
macroglobulin (oc2M) and plasma kallikrein or 
plasmin in plasma under certain pathological 
conditions indicates that this multifunctional 
glycoprotein is also involved in the regulation 
of the blood system cascades. However, pre-
sent evidence suggests a predominant protec-
tive role of a 2-macroglobulin in prevention of 
unspecific proteolysis by inhibition of all 
types of liberated lysosomal proteinases 
(serine, thiol, aspartate, metallo proteinases). 
Due to its high molecular weight, the inhibit-
ory function of a 2 M is normally restricted to 
the vascular bed. oc/-Proteinase inhibitor 
((XjPI), the major antagonist of the lysosomal 
neutrophil elastase, is present in remarkable 
high concentration in blood, but occurs also in 
interstitial fluid and mucous secretions. 0C[-
Antichymotrypsin {a}AC)y a rapidly respond-
ing acute phase reactant, is a potent inhibitor 
of lysosomal neutrophil cathepsin G and mast 
cell chymase. Compared to a t PI and (Y|AC, 
the plasma concentrations of the other given 
inhibitors are clearly lower. Nevertheless, the 
proteinase inhibitors represent approximately 
60% of the plasma proteins other than albu-
min and the immunoglobulins. This is an indi-
rect indication upon the significance of pro-
teinase inhibitors as regulatory proteins of the 
organism. 
Inhibition of activated or liberated proteinases 
by the given inhibitors means that formation 
of vasoactive or toxic peptides such as kinins 
or anaphylatoxins is also depressed. The same 
is true for proteolysis-induced stimulation of 
cellular systems like thrombin-induced 
platelet aggregation or the anaphylatoxin-in-
duced chemotactic response to granulocytes. 
Therefore, inactivation of the regulatory pro-
teinase inhibitors of the blood systems by un-
specific proteolysis represents one of the most 
striking pathological effects caused by 
lysosomal proteinases. 
Even c*j -proteinase inhibitor is proteolytically 
inactivated by a lysosomal metallo enzyme 
from macrophages12, the lysosomal thiol pro-
teinase cathepsin B and a bacterial elastase11. 
Moreover, oxidation of the methionine residue 
in the enzyme-reactive site of a/-proteinase in-
hibitor leads to a significant reduction of the 
affinity of this inhibitor to neutrophil elas-
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tase13. Such oxidizing agents, for example, 
superoxide anion, hydroxyl radicals and hyd-
rogen peroxide, are produced in high amounts 
in the phagolysosomes to facilitate together 
with myeloperoxidase intracellular protein 
breakdown. I f they are released simultane-
ously with the lysosomal enzymes under 
pathological conditions, they may impair loc-
ally the inhibition of extracellularly liberated 
elastase, because the complex formed with 
oxidized a|PI is readily dissociated by sub-
strates exhibiting high affinity for elastase 
(e.g. elastin). This might lead to tissue injury 
following rapid accumulation of polymor-
phonuclear granulocytes in the lungs during 
the inflammatory response. 
In view of the pathogenesis of multiple organ 
failure the imbalance of the physiological 
equilibrium between proteinases and their in-
hibitors should be seriously considered as a 
major reason of the underlying pathological 
mechanism. 
Clinical Studies 
a) Hyperdynamic septic shock 
Our first clinical study on septicemia was per-
formed on patients (n = 18) suffering from 
strictly defined hyperdynamic septic shock 1 4. 
Hemodynamic and biochemical parameters 
were evaluated in suitable time intervals t i l l 96 
hours after taking the initial values at diagnosis 
of hyperdynamic shock (x 0—x 9 6). Within the 
observation period 4 patients died, whereas 
the others survived the shock event. How-
ever, all these patients except 1 succumbed 
within 6 to 84 days after the end of the investi-
gation, either due to direct sequels of shock 
(respiratory insufficiency, oliguria or anuria) 
or to toxic heart failure and malignant disease. 
Besides various other plasma proteins the concen-
trations of a2-macroglobulin were determined by 
radial immunodiffusion with standardized im-
munodiffusion plates (Behringwerke, Marburg). 
Estimation of antithrombin I I I concentration in 
plasma was carried out by electro-immunodiffu-
sion according to LaureW*. The functional activity 
of the fibrin stabilizing factor X I I I was checked by 
the "Clotting Factor X I I I Rapid Reagent" 
(Behringwerke, Marburg). Native inter-cv-trypsin 
inhibitor (ITI 160000) and its acid stable degrada-
tion product (ITI 30000) in serum were detected as 
described recently16. 
Although the hyperdynamic shock phase is 
commonly considered to be the initial stage of 
the disorder, the present results demonstrate 
that the plasma levels of the measured 
parameters were already abnormal when the 
first clinical and hemodynamic signs of septic 
shock appeared (Tab. 1). 
There is good evidence to assume that the sub-
stantial consumption or turnover of plasma 
proteinase inhibitors during the observation 
period is an essential though indirect indica-
tion of the considerable liberation of pro-
teinases in septic shock: 
Consumption of antithrombin I I I , the most 
important inhibitor for maintaining homeos-
tasis of the clotting system1 7, normally reflects 
the liberation of thrombin and factor Xa; their 
inhibition and elimination is primarily ef-
Table 1 Plasma or serum levels of various proteins in 
septic shock 
Parameters x 0 ( ± S E M ) x 9 6 ( ± S E M ) 
factor XI11 46.1 ± 4 . 9 52.9 ± 4.8 
(% of normal) 
antithrombin III 47.4 ± 2.8 58.9 ± 5 . 6 
(% of normal) 
a'2-macroglobulin 48.8 ± 5 . 2 46.8 ± 4 . 5 
(% of normal) 
inter-cv-trypsin 
inhibitor (mlU/ml) 
native, acid-labile 42.7 ± 3 . 6 46.4 ± 3 . 4 
acid-stable 15 .7± 1.7 21.7 ± 2 . 5 
Values are given as mean x (± SEM) for the beginning of the shock 
phase (x0) and after 96 h (x 9 6). 
Normal value for factor XIII, antithrombin III and cv2-macroglobulin: 
100% pool plasma 
Normal range for inter-cv-trypsin inhibitor: 
native, acid-labile: 50 -80 mlU/ml; 
acid-stable: 6 - 9mlU7ml. 
mlU = milli inhibitor units 
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fected by A T I I I . During heparin medication 
to prevent thrombosis or disseminated in-
travascular coagulation, the consumption of 
A T I I I is even further intensified, since the 
heparin-AT I I I complex also reacts with other 
activated clotting enzymes or plasma kalli-
krein 1 8 . Most remarkably, in patients surviv-
ing the shock phase (n = 15), the A T I I I level 
increased continuously, whereas in those who 
died (n = 3) close to the end of the observation 
period A T I I I levels decreased dramatically 
(Fig. 1). Although in vitro effects should be 
transferred to in vivo conditions only with re-
servation, we suppose that at least part of 
A T I I I consumption measured in the present 
trial may be due to proteolysis by granulocytic 
proteinases6, especially in the patients who 
died during the septic shock phase. 
The very low level of a 2-macroglobulin 
throughout the septic shock phase is especially 
striking. Obviously, considerable amounts of 
various proteinases were permanently re-
leased into the circulation and eliminated by 
oc2M. Considering this finding, an important 
function can be ascribed to a 2 M in protecting 
the organism against non-specific proteolysis 
during septic shock. 
In vitro investigations showed that especially 
granulocytic elastase was able to split off most 
rapidly an acid-stable inhibitor ( I T I 30000) 
from native inter-a-trypsin inhibitor ( IT I 
160 000) l 9 . Since in the present study the level 
of native I T I was significantly reduced 
whereas the concentrations of the acid-stable 
ITI-derived inhibitor was considerably ele-
vated, it may be deduced that granulocytic 
proteinases are responsible for the prominent 
turnover of I T I in septic shock and septicemia. 
Measurement of the I T I turnover could be an 
indirect marker of leukocytic proteinase activ-
ity although the biological function of I T I 
160000 or I T I 30000 is not yet clear. 
Besides turnover or consumption of several 
plasma proteinase inhibitors, the significantly 
low level of the fibrin stabilizing clotting fac-
tor X I I I may be also indicative of enhanced 
proteolytic activity due to degranulation of 
leukocytes. F X I I I seems to be a preferred 
substrate of granulocytic proteinases, since in 
experimental septicemia the high consump-
tion of this clotting factor could be prevented 
by previous systemic application of a specific 
inhibitor of granulocytic elastase and cathep-
sin G 2 0 . Moreover, Egbring et al . 2 1 de-
Fig. 1: Plasma levels of antithrombin III (AT III) during 96 h of hyperdynamic septic shock. Indicated are mean values 
x (± SEM) of patients (n = 15) surviving the shock phase (- • - • - ) , of patients (n = 3) who died close to the end of the 
observation period ( ) and of the whole group (n = 18, ). 
Normal range: 75—100% of pool plasma. 
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monstrated that in the course of septicemia in 
man the active transglutaminase (subunit A) 
and the carrier protein (subunit S) of F X I I I 
were consumed to a comparable degree. The 
reduction of both subunits, however, is not 
consistent with the usual consumption of 
F X I I I during blood clotting, since subunit A 
and F X I I I activity disappear completely after 
coagulation of plasma, whereas subunit S re-
mains unchanged. As the elastase-like 
granulocytic proteinase (ELP) caused a similar 
reduction of the activity of both F X I I I sub-
units in plasma21, it is very likely that pro-
teolysis by ELP is involved in patients with 
septicemia or septic shock. 
b) Major surgery and septicemia 
To verify the release of granulocytic pro-
teinases into patient's plasma in severe inflam-
mation, we used the P M N granulocytic elas-
tase as a marker enzyme. The liberated pro-
teinase is present in the circulation primarily 
in form of the elastase-cV|-proteinase inhibitor 
(E-(YiPI) complex. A small amount of neu-
trophil elastase may be bound also to a2-mac-
roglobulin, however, compared to the E-c^PI 
complex the E-a' 2M complex is much more 
rapidly eliminated from the circulation 2 2. 
In the prospective clinical study, plasma was 
drawn in suitable time intervals from patients 
subjected to major abdominal surgery, fol-
lowed either by uncomplicated recovery 
(group A, n. = 11) or by septicemia (groups B, 
n — 14, and C, n = 16). Patients of group B 
survived the infection, whereas patients of 
group C died due to severe septicemia or sep-
tic shock2. 
Evaluation of the amount of complexed elastase 
was performed with an enzyme-linked immunoas-
say23 now commercially available (PMN Elastase, 
E. Merck, Darmstadt). The inhibitory activity of 
AT I I I against thrombin was determined using the 
chromogenic peptide substrate S-2238 (Deutsche 
Kabi, München). The biological activity of F X I I I 
was assayed with the "Clotting Factor X I I I Rapid 
Reagent" (Behringwerke, Marburg). The inhibit-
ory activity of a'2M was detected with an a2-Mac-
roglobulin Test Combination (Boehringer, Mann-
heim) according to Ganrotb24. 
The changes in the plasma levels of complexed 
elastase (E-cc/PI) are summarized for each 
group in Figure 2 (lower part): 
Patients without postoperative infection 
showed only a moderate (up to threefold) in-
crease of the preoperative value (60—120 ng/ 
ml)* following surgery, whereas the septic pa-
tients exhibited multiple elevated levels in the 
septic phase. Therefore, blood specimens 
should be taken at least every 6 to 12 hours 
during the acute phase of an inflammatory 
process. 
At the time of diagnosis of septicemia highly 
significantly elevated E-afiPI levels were mea-
sured corresponding to an up to sixfold or 
even tenfold mean increase in groups B and C. 
Individual peak levels were found to be as high 
as 2500 ng/ml in both groups. In patients with 
persisting septicemia the E-cvjPI levels re-
mained high until lethal outcome (group C), 
whereas recovery from septicemia was re-
flected by a simultaneous decrease of the 
E-QfiPI levels to the normal range (group B). 
Concomitant to the increase oj complexed elas-
tase in plasma a significant decrease of the in-
hibitory activity of AT III and a2M as well as 
of the fibrin stabilizing activity of F XIII could 
be demonstrated (Fig. 2). The diminished ac-
tivities of these factors at onset of septicemia 
were normalized in all patients overcoming 
the infection (group B), whereas a further sig-
nificant decrease was found in those who died 
(group C). 
c) Multiple trauma and infection 
More recently, we were able to measure the 
liberation of granulocytic myeloperoxidase 
::' The preoperative mean value of group C was already 
elevated: of these patients 6 individuals suffered from 
defined infections before operation. Surgical removal 
of the infection focus may have caused the slight mean 
decrease of the E-o^PI complex following operation. 
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Fig. 2: Plasma levels (mean ± SEM) of elastase-aj-pro-
teinase inhibitor complex (E-a|PI), antithrombin I II 
(AT III ) , <x2-macroglobulin (a 2 M) and factor X I I I ( F X I I I ) 
in patients subjected to major abdominal surgery: 
A = patients without postoperative infection (n = 11) 
B = patients surviving postoperative septicemia (n = 14) 
C = patients dying due to septicemia or septic shock (n 
= 16) 
Values are given for the day before operation, the day 
after operation, the early postoperative phase, at onset of 
sepsis and during septicemia. Last determinations were 
performed on day of discharge (D) for group A, on day of 
recovery (R) for group B and before death (f) for group C . 
nr = normal range. 
and lactoferrin from P M N granulocytes into 
plasma by specific enzyme-linked immuno-
sorbent assays. These assays have been de-
veloped by S. Neumann and W. Rautenberg 
(Biochemical Research Department, E. 
Merck, Darmstadt) and are not yet commer-
cially available. 
Normal plasma concentrations of 
myeloperoxidase and lactoferrin were found 
to be 20-60 ng/ml and 100-300 ng/ml, re-
spectively. 
First data of a patient suffering from multiple 
trauma with lung contusion showed a con-
comitant release of elastase, myeloperoxidase 
and lactoferrin (Fig. 3). The severity of the 
trauma was indicated by the highly elevated 
levels of all three granulocytic proteins at the 
time of the first measurement (6 hours post 
trauma). The subsequent pattern of the plasma 
levels of all three lysosomal proteins reflected 
quite perfectly infectious complications 
(pneumonia) at days 2—3 and 4 — 5 after 
trauma as well as the amelioration of the clini-
cal situation of the patient in the posttraumatic 
course. 
Remarkably, a perfect correlation existed in 
the patient's plasma not only between the 
azurophilic elastase and myeloperoxidase 
levels but also between these enzymes and lac-
toferrin from the specific granules. This 
suggests, that both types of granules have been 
equally involved in phagocytosis and extracel-
lular liberation of the lysosomal proteins in 
the underlying kind of inflammation. 
Whether the same holds true for other inflam-
matory processes is currently under investiga-
tion. 
In general, elevated plasma levels of 
granulocytic lysosomal proteins indicate par-
ticipation of polymorphonuclear granulocytes 
in an inflammatory event taking place 
elsewhere in the organism. The amount of the 
E-a|PI complex as well as of myeloperoxidase 
and lactoferrin seems to reflect the intensity of 
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Fig. 3: Plasma levels of complexed elastase (E-o:]PI), myeloperoxidase and lactoferrin in a patient suffering from severe 
multiple trauma. 
Normal range: complexed elastase = 60—120 ng/ml, 
myeloperoxidase = 20—60 ng/ml, 
lactoferrin = 100-300 ng/ml. 
both the inflammatory stimulus and the re-
sponse thereto of the neutrophils. 
In our opinion, lysosomal and other cell-de-
rived proteinases are preferential candidates 
for establishing a diagnostic pattern of an in-
flammatory response for mainly two reasons: 
(i) Due to their high potential for inactivation 
of plasma proteins and structural elements by 
degradation or production of inflammatory 
mediators proteinases represent most interest-
ing tools for elucidation of pathomechanisms 
and (ii) they offer means for therapeutic ap-
proaches with suitable exogenous proteinase 
inhibitors. 
Experimental Animal Studies 
Administration of a potent inhibitor of 
granulocytic elastase and cathepsin G (Bow-
man-Birk inhibitor from soybeans) di-
minished considerably the endotoxin-induced 
consumption of various plasma factors includ-
ing antithrombin I I I and factor X I I I in dogs2\ 
With regard to the role of granulocytic pro-
teinases in inflammatory diseases like septic 
shock and multiple trauma further therapeutic 
approaches with generally available proteinase 
inhibitors seemed to be desirable. Eglin, a po-
tent inhibitor of P M N elastase and cathepsin 
G 2 6 from the leech Hirudo medicinalis, is now 
available by genetic engineering27 in quantities 
sufficient for experimental studies (Ciba 
Geigy, Basel). In order to elucidate the poten-
tial therapeutic effectiveness of this minipro-
tein in severe inflammation we have developed 
a septicemia model in pigs 2 8. 
Septicemia was induced by i.v. infusion of 3 x 
10 i 0 E. coli for 2 hours. In another group eglin 
was simultaneously applied for 4 hours in a 
dose of 3.85 mg x kg - 1 x h _ 1 giving rise to 
plasma levels up to 6 jimol/l. 
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Compared to the untreated septicemia group 
with a mean survival time of 6 hours, most of 
the eglin-treated animals survived the experi-
mental period of 30 hours. 
The therapeutic effectiveness of eglin was cor-
roborated by improvement of many of the 
parameters measured, especially by (a) only 
modest morphological alterations of the lungs 
(i.e. less interstitial edema formation), (b) a 
minor rise in extravascular lung water, (c) di-
minished consumption of antithrombin III, 
factor XIII and ocj-macroglobulin, (d) and 
only a retarded and weak increase in body 
temperature. 
In animals with normal kidney function, eglin 
was excreted in urine to 75 — 95% within 12 
hours. Accumulation in plasma, however, oc-
cured in pigs with renal insufficiency due to 
local microthrombi formation which clearly 
was not abolished by eglin treatment. There-
fore, thrombin inhibitors, e.g. hirudin from 
the leech, have to be administered in addition 
to diminish activation of the coagulation cas-
cade under these circumstances29. Details of 
studies in which aprotinin, Cl-inactivator and 
superoxide-dismutase (as a radical scavanger) 
also showed discrete therapeutic effects wil l be 
presented elsewhere. 
Conclusion 
Summarizing the results of our clinical and ex-
perimental animal studies, it is obvious that in 
sepsis and septic shock the natural defence 
mechanisms against augmented proteolysis are 
considerably overstressed thus leading to fatal 
consumption of many vital plasma proteins 
and to development of multiple organ failure. 
Administration of suitable proteinase in-
hibitors should primarily prevent the exhaus-
tion of endogenous plasma inhibitors. Unt i l 
such inhibitors are available for use in hu-
mans, substitution with fresh frozen plasma 
or antithrombin I I I concentrates30 seems to be 
:he method of choice. 
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